Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17


CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.

Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ.

Nat Commun. 2017 Jan 6;8:13897. doi: 10.1038/ncomms13897.


Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.

Veracini L, Grall D, Schaub S, Beghelli-de la Forest Divonne S, Etienne-Grimaldi MC, Milano G, Bozec A, Babin E, Sudaka A, Thariat J, Van Obberghen-Schilling E.

Oncotarget. 2015 Apr 10;6(10):7570-83.


AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12.


Tumor and stromal-based contributions to head and neck squamous cell carcinoma invasion.

Markwell SM, Weed SA.

Cancers (Basel). 2015 Feb 27;7(1):382-406. doi: 10.3390/cancers7010382. Review.


ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.

Buonato JM, Lazzara MJ.

Cancer Res. 2014 Jan 1;74(1):309-19. doi: 10.1158/0008-5472.CAN-12-4721. Epub 2013 Oct 9.


Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target.

Rasanen K, Sriswasdi S, Valiga A, Tang HY, Zhang G, Perego M, Somasundaram R, Li L, Speicher K, Klein-Szanto AJ, Basu D, Rustgi AK, Speicher DW, Herlyn M.

Mol Cell Proteomics. 2013 Dec;12(12):3778-92. doi: 10.1074/mcp.M113.029587. Epub 2013 Sep 13.


EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas.

Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND, Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M.

Mol Cancer Ther. 2013 Oct;12(10):2176-86. doi: 10.1158/1535-7163.MCT-12-1210. Epub 2013 Aug 12.


Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.

Weng D, Song B, Koido S, Calderwood SK, Gong J.

J Immunol. 2013 Jul 15;191(2):755-63. doi: 10.4049/jimmunol.1203286. Epub 2013 Jun 14.


Joint TGF-β type II receptor-expressing cells: ontogeny and characterization as joint progenitors.

Li T, Longobardi L, Myers TJ, Temple JD, Chandler RL, Ozkan H, Contaldo C, Spagnoli A.

Stem Cells Dev. 2013 May 1;22(9):1342-59. doi: 10.1089/scd.2012.0207. Epub 2013 Feb 15.


Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

Markovic A, Chung CH.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1149-59. doi: 10.1586/era.12.91. Review.


Stem-like cells and therapy resistance in squamous cell carcinomas.

Facompre N, Nakagawa H, Herlyn M, Basu D.

Adv Pharmacol. 2012;65:235-65. doi: 10.1016/B978-0-12-397927-8.00008-7. Review.


The mesenchymal tumor microenvironment: a drug-resistant niche.

Cukierman E, Bassi DE.

Cell Adh Migr. 2012 May-Jun;6(3):285-96. doi: 10.4161/cam.20210. Epub 2012 May 1. Review.


Mtss1 regulates epidermal growth factor signaling in head and neck squamous carcinoma cells.

Dawson JC, Timpson P, Kalna G, Machesky LM.

Oncogene. 2012 Apr 5;31(14):1781-93. doi: 10.1038/onc.2011.376. Epub 2011 Sep 19.


Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer.

Yang Y, Nakagawa H, Tetreault MP, Billig J, Victor N, Goyal A, Sepulveda AR, Katz JP.

Cancer Res. 2011 Oct 15;71(20):6475-84. doi: 10.1158/0008-5472.CAN-11-1702. Epub 2011 Aug 25.


Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas.

Basu D, Montone KT, Wang LP, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, Herlyn M.

Cell Cycle. 2011 Jun 15;10(12):2008-16. Epub 2011 Jun 15.


Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab.

Brand TM, Iida M, Wheeler DL.

Cancer Biol Ther. 2011 May 1;11(9):777-92. Epub 2011 May 1. Review.

Supplemental Content

Support Center